<DOC>
	<DOCNO>NCT00509665</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together doxorubicin work treat patient recurrent progressive head neck cancer .</brief_summary>
	<brief_title>Gemcitabine Doxorubicin Treating Patients With Recurrent Progressive Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine overall response rate ( complete partial response ) produce combination gemcitabine hydrochloride doxorubicin hydrochloride patient recurrent progressive head neck cancer . Secondary - To describe overall progression-free survival patient treat chemotherapy combination . - To describe duration response ( complete partial response ) among patient attain response . - To evaluate toxicity associate administration combination previously treat head neck cancer patient . - To establish correlation cytotoxicity agent cell cycle-arrest apoptosis cancer cell , particularly involve sphingolipid pathway . OUTLINE : Patients receive gemcitabine hydrochloride IV 30 minute doxorubicin hydrochloride IV 5-10 minute day 1 8 . Treatment repeat every 3 week least 2 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline every 2 course correlative study . Samples analyze plasma/serum sphingosine-1-phosphate , ceramide , marker apoptotic pathway via LC/MS . After completion study treatment , patient follow every 6 month 3 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically cytologically confirm head neck cancer Recurrent progressive disease Must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Must receive prior platinumbased chemotherapy regimen ( cisplatin carboplatin ) without radiotherapy , unless patient deem unsuitable platinumbased therapy due renal dysfunction clinical contraindication Exclusion criterion : Known brain metastasis PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status ( PS ) ≤ 2 OR Karnofsky PS ≥ 60 % Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/µL Total bilirubin ≤ 1.5 mg/dL AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x institutional upper limit normal Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 30 mL/min Females reproductive potential must plan conceive child study treatment period must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry duration study Exclusion criterion : Not pregnant breastfeed History allergic reaction attribute compound similar chemical biological composition gemcitabine hydrochloride doxorubicin hydrochloride Lower normal cardiac ejection fraction Patients must echocardiogram MUGA scan prior use study drug Uncontrolled intercurrent illness would limit compliance study requirement include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation Clinical AIDS know positive HIV serology PRIOR CONCURRENT THERAPY : Inclusion criterion : Recovered prior therapy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) At least 30 day since prior experimental agent At least 4 week since prior radiotherapy palliation primary tumor Exclusion criterion : Prior gemcitabine hydrochloride doxorubicin hydrochloride Concurrent hormones chemotherapeutic agent , except steroid give adrenal failure , hormone give nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent use dexamethasone antiemetic Concurrent palliative radiotherapy Other concurrent investigational commercial agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
</DOC>